<SEC-DOCUMENT>0001564590-20-038023.txt : 20200807
<SEC-HEADER>0001564590-20-038023.hdr.sgml : 20200807
<ACCEPTANCE-DATETIME>20200806213204
ACCESSION NUMBER:		0001564590-20-038023
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20200805
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200807
DATE AS OF CHANGE:		20200806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		201083540

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>staa-8k_20200805.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-08-07T01:15:11.5306975+00:00 -->
<!-- Version            : 5.0.1.476 -->
<!-- Package ID         : 50ea8424e897458085bf3ed531f5ee62 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:staa="http://www.staar.com/20200805" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
staa-8k_20200805.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000718937_20200805_20200805">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000718937_20200805_20200805">0000718937</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="staa-20200805.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000718937_20200805_20200805">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-05</xbrli:startDate>
					<xbrli:endDate>2020-08-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;margin-bottom:0pt;margin-top:3pt;margin-left:37.49%;margin-right:34.51%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">U<span style="letter-spacing:-0.05pt;">N</span>IT<span style="letter-spacing:-0.05pt;">E</span>D S<span style="letter-spacing:0.05pt;">T</span>A<span style="letter-spacing:0.05pt;">T</span>ES</p>
<p style="text-align:center;margin-bottom:0pt;line-height:20pt;margin-top:0pt;margin-left:14.71%;margin-right:11.75%;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S<span style="letter-spacing:-0.05pt;">E</span>C<span style="letter-spacing:-0.05pt;">U</span><span style="letter-spacing:0.05pt;">R</span>IT<span style="letter-spacing:-0.1pt;">I</span><span style="letter-spacing:0.1pt;">E</span>S A<span style="letter-spacing:-0.05pt;">N</span>D E<span style="letter-spacing:0.2pt;">X</span>CHA<span style="letter-spacing:-0.05pt;">N</span>GE<span style="letter-spacing:0.05pt;"> </span>CO<span style="letter-spacing:-0.05pt;">M</span>MISSION</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:37.46%;margin-right:35.07%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WAS<span style="letter-spacing:0.05pt;">H</span>IN<span style="letter-spacing:-0.1pt;">G</span>TON, DC<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">2</span>0549</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000718937_20200805_20200805">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-left:40.3%;margin-right:40.3%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:33.24%;margin-right:30.41%;text-indent:0.01%;font-weight:bold;font-size:12pt;font-family:Times New Roman;letter-spacing:-0.15pt;font-style:normal;text-transform:none;font-variant: normal;">P<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:0.05pt;">u</span>a<span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>tion<span style="letter-spacing:0.1pt;"> </span>13 or<span style="letter-spacing:-0.05pt;"> </span>15(d) of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e <span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">ec</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ities Excha<span style="letter-spacing:0.05pt;">n</span>ge<span style="letter-spacing:-0.05pt;"> </span>A<span style="letter-spacing:0.05pt;">c</span>t of<span style="letter-spacing:0.05pt;"> </span>1934</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;line-height:13pt;margin-top:0pt;margin-left:17.08%;margin-right:14.74%;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Da<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>t<span style="letter-spacing:0.05pt;"> </span>(<span style="letter-spacing:-0.05pt;">D</span>a<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">r</span>l<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">e</span>st <span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.1pt;">v</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t <span style="letter-spacing:-0.1pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:0.05pt;">r</span>t<span style="letter-spacing:-0.1pt;">e</span><span style="letter-spacing:0.05pt;">d)</span>: <span style="letter-spacing:-0.7pt;"> </span><ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000718937_20200805_20200805" format="ixt:datemonthdayyearen">August 5, 2020</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:7pt;text-indent:0%;font-size:7.5pt;">&#160;</p>

<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.41%;margin-right:28.17%;text-indent:0%;font-weight:bold;color:#000000;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000718937_20200805_20200805">STAAR Surgical Co</ix:nonNumeric>mpany<span style="letter-spacing:0.05pt;color:#000000;"> </span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;line-height:11pt;margin-left:30.35%;margin-right:28.17%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-style:normal;text-transform:none;font-variant: normal;">(<span style="letter-spacing:-0.05pt;">Ex</span>act<span style="letter-spacing:-0.25pt;"> </span>N<span style="letter-spacing:0.2pt;">a</span><span style="letter-spacing:-0.15pt;">m</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Re<span style="letter-spacing:0.1pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>trant<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">p</span>ecified<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">i</span>n<span style="letter-spacing:-0.1pt;"> </span>Charter)</p>
<p style="margin-bottom:0pt;line-height:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000718937_20200805_20200805">0-11634</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000718937_20200805_20200805">95-3797439</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000718937_20200805_20200805">25651 Atlantic Ocean Drive</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000718937_20200805_20200805">Lake Forest</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000718937_20200805_20200805">92630</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: <span style="text-decoration:underline;font-family:Times New Roman;"><ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000718937_20200805_20200805">626</ix:nonNumeric></span>-<ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000718937_20200805_20200805">303-7902</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0.93%;margin-right:1.87%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Che<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he a<span style="letter-spacing:0.05pt;">ppropr</span>iate<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">bo</span>x<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.1pt;">l</span><span style="letter-spacing:0.15pt;">o</span>w<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:0.1pt;"> </span>the F<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:0.15pt;">r</span>m<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">8</span><span style="letter-spacing:-0.1pt;">-</span>K <span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>ten<span style="letter-spacing:0.05pt;">d</span>ed<span style="letter-spacing:-0.25pt;"> </span>to s<span style="letter-spacing:0.1pt;">i</span>mult<span style="letter-spacing:0.1pt;">a</span>ne<span style="letter-spacing:0.05pt;">o</span>u<span style="letter-spacing:0.1pt;">sl</span>y<span style="letter-spacing:-0.65pt;"> </span>sati<span style="letter-spacing:0.1pt;">s</span><span style="letter-spacing:0.05pt;">f</span>y<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>il<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">ob</span>l<span style="letter-spacing:0.1pt;">i</span>gati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>the <span style="letter-spacing:0.15pt;">r</span>egistr<span style="letter-spacing:0.15pt;">a</span>nt un<span style="letter-spacing:0.05pt;">d</span>er<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">t</span>he <span style="letter-spacing:-0.1pt;">f</span><span style="letter-spacing:0.05pt;">o</span>ll<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">pro</span>visi<span style="letter-spacing:0.15pt;">o</span>ns<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.25pt;">(</span><span style="font-style:italic;">s</span><span style="font-style:italic;">ee</span><span style="font-style:italic;"> </span>G<span style="letter-spacing:0.15pt;">e</span>ne<span style="letter-spacing:0.05pt;">r</span>al<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">I</span>n<span style="letter-spacing:0.1pt;">s</span>tructi<span style="letter-spacing:0.15pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>.<span style="letter-spacing:0.05pt;">2</span>.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">b</span>el<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.25pt;">w</span><span style="letter-spacing:0.05pt;">)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:6pt;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:96.04%;">
<tr>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
<td style="width:32.01%;"></td>
</tr>
<tr>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000718937_20200805_20200805">Common</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000718937_20200805_20200805">STAA</ix:nonNumeric></p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000718937_20200805_20200805">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;line-height:11pt;margin-top:0pt;margin-left:0.93%;margin-right:0.56%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> m</span>a<span style="letter-spacing:0.15pt;">r</span>k<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">e</span>ther<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>i<span style="letter-spacing:-0.05pt;">s</span>tr<span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>pany<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>defi<span style="letter-spacing:-0.05pt;">n</span>ed<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>R<span style="letter-spacing:-0.05pt;">u</span>le<span style="letter-spacing:-0.2pt;"> </span>405<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">o</span>f<span style="letter-spacing:-0.15pt;"> </span>1<span style="letter-spacing:-1.8pt;"> </span>933 (17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;230<span style="letter-spacing:-0.1pt;">.</span>405)<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> Ru</span>le<span style="letter-spacing:-0.2pt;"> </span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.25pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Se<span style="letter-spacing:0.15pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>rities<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.15pt;">E</span><span style="letter-spacing:-0.05pt;">x</span><span style="letter-spacing:0.15pt;">c</span>han<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>1934<span style="letter-spacing:-0.15pt;"> </span>(17<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">C</span>FR<span style="letter-spacing:-0.25pt;"> </span>&#167;240<span style="letter-spacing:-0.1pt;">.</span>1<span style="letter-spacing:-0.05pt;">2</span><span style="letter-spacing:0.3pt;">b</span><span style="letter-spacing:-0.1pt;">-</span>2).</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.94%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.15pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E<span style="letter-spacing:-0.2pt;">m</span>e<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.05pt;">r</span>o<span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">t</span>h<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span><span style="letter-spacing:0.05pt;">p</span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:1.3pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.3pt;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000718937_20200805_20200805" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;line-height:5pt;text-indent:0%;font-size:5.5pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">e</span><span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.15pt;">o</span><span style="letter-spacing:-0.1pt;">w</span>th<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.2pt;">o</span><span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.2pt;">y</span>,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>dicate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">b</span>y<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:0.15pt;">c</span>k<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ark<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">i</span>f<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>istra<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">h</span>as<span style="letter-spacing:-0.15pt;"> </span>elected<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">n</span>ot<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span><span style="letter-spacing:-0.05pt;">us</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span><span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>t<span style="letter-spacing:0.1pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>ded<span style="letter-spacing:-0.25pt;"> </span>tra<span style="letter-spacing:-0.05pt;">ns</span>i<span style="letter-spacing:0.1pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>period<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:-0.1pt;">f</span>or co<span style="letter-spacing:-0.2pt;">m</span>p<span style="letter-spacing:0.1pt;">l</span><span style="letter-spacing:-0.05pt;">y</span><span style="letter-spacing:0.1pt;">i</span><span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.1pt;">w</span><span style="letter-spacing:0.1pt;">i</span>th<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.15pt;">a</span>ny<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">e</span>w<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">s</span>ed<span style="letter-spacing:-0.1pt;"> f</span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.15pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>cial<span style="letter-spacing:-0.3pt;"> </span>accou<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:0.1pt;">i</span>ng<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:0.1pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>da<span style="letter-spacing:0.4pt;">r</span>ds<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:-0.05pt;">v</span>ided<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;">su</span>a<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">S</span>ection<span style="letter-spacing:-0.35pt;"> </span>13(a)<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>E<span style="letter-spacing:-0.05pt;">x</span>c<span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.15pt;">a</span>n<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">A</span>ct.<span style="letter-spacing:1.8pt;"> </span><span style="font-family:Segoe UI Symbol;letter-spacing:1.8pt;">&#9744;</span></p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;line-height:12pt;margin-top:0pt;margin-left:0.93%;margin-right:2.43%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:MS Mincho;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01 Regulation FD Disclosure.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 5, 2020, the Company held a conference call to discuss the financial results for the quarter ended July 3, 2020.&#160;&#160;A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01 Financial Statements and Exhibits</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.75pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:2.35pt;"></td>
<td style="width:469.75pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Exhibit No.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="staa-ex991_25.htm"><span style="text-decoration:underline;">Transcript of conference call of the Company held on August 5, 2020</span></a><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.72%;"><span style="margin-left:36pt;"></span>&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.5pt;;">
<tr>
<td style="width:85.25pt;"></td>
<td style="width:11.35pt;"></td>
<td style="width:471.9pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.72%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:568.8pt;;">
<tr>
<td style="width:85.3pt;"></td>
<td style="width:18.2pt;"></td>
<td style="width:465.3pt;"></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STAAR Surgical Company&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 6, 2020</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">/s/ Caren Mason</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Caren Mason</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>staa-ex991_25.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
staa-ex991_25.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">STAAR Surgical Q2 2020 Earnings Call Transcript</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: August 5, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CORPORATE PARTICIPANTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical Caren Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER PARTICIPANTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cecilia Furlong, Analyst, Canaccord Genuity LLC</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><br />MANAGEMENT DISCUSSION SECTION</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good afternoon, ladies and gentlemen, and welcome to the STAAR Surgical Second Quarter 2020 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] And please be advised that today's conference is being recorded. [Operator Instructions]</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I would now like to hand the conference over to your speaker today, Mr. Brian Moore and you may begin.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Brian Moore, Vice President-Investor, Media Relations and Corporate Development, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Christi, and good afternoon everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to discuss the company's financial results for the second quarter ended July 3, 2020. On the call today are Caren Mason, President and Chief Executive Officer and Patrick Williams, Chief Financial Officer. The press release of our second quarter results was issued just after 4:00 PM Eastern Time and is now available on STAAR's website at <font style="text-decoration:underline;">www.staar.com</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and prospects.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release, as well as STAAR's public periodic filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes, and does not intend to do so. </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales in constant currency. We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in today's press release. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">themselves </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to two initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperation with this process.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And with that, I would now like to turn the call over to Caren Mason, President and CEO of STAAR</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason - President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Brian. Good afternoon everyone and thank you for joining us on today's call. Let me start by welcoming Patrick Williams. We are delighted to have him on board as our new Chief Financial Officer. Welcome also two our new board members, Dr. Gil Kliman and Tom Frinzi, who joined the board on June 1. I would also like to take this opportunity to express my sincere appreciation to the entire STAAR team for achieving strong results and demonstrating operating discipline during the pandemic.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outlook we provided in May accurately assessed the market dynamics and STAAR's ability to perform well in the midst of a prolonged shutdown of elective surgeries in most of the global markets we serve. While refractive procedures were down significantly or came to a halt in April and May in much of North America, Europe, Latin America, India and the Middle East, continuing recovery and growth were recorded in Japan, Korea and China. In June, year-over-year ICL implant procedures recorded strong growth with units up 65% in Japan, 24% in Rest of Asia-Pacific, 17% in Germany, 15% in Distributor Markets in Europe, and 11% in Korea. The positive trending continues in July with China experiencing stronger than anticipated demand as the peak season began in earnest. While COVID-19 hotspots and government public health mandates may reoccur moving forward, we anticipate less business interruption and continued increased interest in our EVO ICL lens-based refractive solutions in Q3 and Q4. Our team is squarely focused on generating significant growth by supporting our surgeon partners as they restart their practices with patient recruiting programs, training and digital marketing.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As you know, China is the largest market in the world for refractive vision correction. The China peak implant season is underway and our team is pleased with the response by our surgeon partners in quickly moving to a digital platform of patient roadshows, engagement and education that is also supported by marketing and social media campaigns. In fact, one virtual EVO ICL roadshow campaign has the lofty goal of reaching 100 million visitors from 100 cities during Q3. Refractive surgeons are increasing their hours and anticipating strong double-digit growth in the summer months. We continue to believe that we will achieve a 20% share of the refractive procedure market in China by year-end.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We resumed production at our California manufacturing facilities on April 27 following a voluntary six week COVID-19 related pause. We have had a very successful restart that exceeded our expectations and anticipate that we will be able to meet the increased level of demand for both our Spheric and Toric EVO lenses through the remainder of 2020 and beyond. We are also moving forward once again with our plans to restart manufacturing in our Nidau, Switzerland facility in 2021, and we are continuing our work to ready our Lake Forest, California facility for manufacturing our EVO Viva presbyopic lenses.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our US clinical trial for our EVO family of myopia lenses, all 14 of our clinical trial sites resumed patient recruiting, screening and implants in mid-May after various periods of delay due to elective surgery mandated closures </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Q2. Assuming no material change in the current operating environment, we anticipate that we will complete enrollment in the trial by the end of September. When we then consider the subsequent six month patient follow-up and time to prepare our data submission to the FDA, we believe we are on track for potential marketing approval and commercialization of EVO in the US in the second half of 2021. The US is the second largest market in the world for refractive vision correction and we very much look forward to bringing our game-changing EVO lens to US surgeons and their patients.</font></p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Turning to presbyopia, we are extremely pleased to now have CE Mark approval for our Extended Depth of Focus or EDOF presbyopia lens that is designed to correct near, intermediate, and distance vision. We are branding our innovative EDOF lens as EVO Viva. EVO Viva is a new treatment option for potential future consideration by the 1.7 billion people globally with presbyopia who want to get rid of their reading glasses or frequent replacement contact lenses. EVO Viva will initially target the tens of millions of eyes of opportunity for early presbyopes ages 45 to 55 in the 31 countries recognizing the CE Mark through a phased rollout beginning in Spain, Belgium and Germany.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate the first implants will occur in September following physician training and certification. Our aim with EVO Viva is to achieve high levels of patient satisfaction and true visual freedom. Commercialization of EVO Viva will be supported by consumer facing social media, supporting our See Young Again! and Rewind your Vision messaging. Also clinical papers have already been submitted for peer review and publication by our clinical trial surgeon principal investigators and medical monitor.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Looking ahead to the remainder of 2020, the impact on our sales related to COVID-19 appears to be lessening, particularly outside the US where STAAR generates more than 95% of its revenue. Globally, our ophthalmic customers also expressed to us that they have no desire to pause procedures again unless mandated to do so with many determined to work through the traditional summer holidays. Where hotspots do occur, we expect any pause in refractive vision correction procedures to be brief in duration and limited in scope.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With that said, the third quarter has historically been one of our strongest revenue quarters with China and other Asian countries leading the way. Our outlook for Q3 currently anticipates a sequential revenue increase of at least 20% from our Q2 results which would then result in year-over-year double digit growth for the quarter.</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At this point, we expect fourth quarter revenue will be very similar to third quarter as high-volume seasonality tapers off in China but we see traditional seasonal increases in our other markets. It is my pleasure now to ask Patrick to report on our financial results. Patrick?</p>
<p style="text-align:justify;margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams - Chief Financial Officer, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you for the warm welcome Caren and good afternoon everyone. Total net sales for Q2 2020 were $35.2 million consistent with Q1 2020 net sales and down compared to the $39.7 million for Q2 2019. The year-over-year decline was associated with the various COVID related market closures Caren mentioned earlier.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In terms of product mix, ICL sales represented 87% of total company net sales for the Q2 of 2020 and </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ther </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">P</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">roducts represented 13% which is consistent with Q2 2019 results. Gross profit for Q2 2020 were $24.4 million or 69.4% of net sales as compared to gross profit of $24.8 million or 70.4% of net sales for Q1 2020 and $29.9 million or 75.4% of net sales for Q2 2019.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sequential decrease in gross margin for the quarter is primarily due to approximately $1 million in period expenses related to a voluntary six-week COVID-19 manufacturing pause that did conclude at the end of April, period costs associated with the manufacturing expansion projects and geographic sales mix. Compared to prior year results, the decrease was primarily attributable to geographic sales mix and the aforementioned manufacturing costs.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moving into the second half of 2020, we would expect to see gross margin increase from here into the low 70% range as our production volume scale back up to support the higher anticipated sales for the second half. Now moving down the income statement, total operating expenses for Q2 2020 were $25.5 million, slightly down compared to $25.9 million for Q1 2020 and slightly up compared to Q2 2019 at $25.3 million as the company continued its cost containment measures related to nonessential variable costs while expanding programs designed to fuel growth and clinical excellence.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taking a closer look at the components of operating expenses, G&amp;A expense for Q2 2020 was $7.8 million compared to the $8 million for Q1 2020 and $7.5 million for Q2 2019. The decrease from prior quarter was due to a decrease in tax consulting costs and travel related expenses offset by higher head count and salary related expenses. The year-over-year is due to overall higher head count and salary related expenses, partially offset by a decrease in variable compensation and travel expenses. Moving into the second half of the year, we expect G&amp;A expense to move up slightly going into the third quarter as we ramp-up some activities and then remain flat moving into Q4.Sales and marketing expense was $10.3 million for Q2 2020 compared to $11 million for Q1 2020 and $11.7 million for Q2 2019. The decrease from prior quarter and prior year was due to lower trade show expenses and travel expenses as a result of lower activities due to COVID, offset by an increase in advertising and promotional activities and salary related expenses. As we move into our seasonally busiest quarter and with many of our markets beginning to open up from the COVID shutdown, we will be ramping up our sales and marketing investments and expect to see absolute dollar expense levels very similar by quarter to what we did in Q3 and Q4 of 2019 respectively. Research and development expense was $7.3 million in Q2 2020 compared to$6.9 million for Q1 2020 and $6.1 million for Q2 2019. The increase in research and development expense was due to increased clinical expenses associated with our EVO clinical trial in the US and increased head count and salary related expenses, partially offset by lowering variable compensation and travel expense.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a percent of sales, R&amp;D has been running at approximately 20% of sales by quarter in the first half of 2020 and we would expect a similar percent of sales as we continue to enroll and follow up on our pivotal US EVO clinical trial. The operating loss in Q2 2020 was $1.1 million compared to a $1.1 million operating loss for Q1 of 2020 and an operating profit of $4.6 million for Q2 2019. Net loss for the second quarter of 2020 was $1.2 million or $0.03 per share compared to $134,000 or $0.00 loss per share in Q1 2020. And net income of $3.9 million or $0.08 per share for Q2 2019. On a non-GAAP basis, adjusted net income for Q2 2020 was $1.4 million or $0.03 per share compared to adjusted net income of $1.9 million or $0.04 per share for Q1 2020 and $6.5 million or $.014 per share for Q2 2019.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>A table reconciling the GAAP information to the non-GAAP information is included in today's financial release. Turning now to our balance sheet, our cash and cash equivalents as of July 3, 2020 totaled $116.3 million, up $5.4 million compared to $110.9 million at the end of the first quarter 2020. The sequential increase was primarily attributable to proceeds from the exercise of stock options. Before we open the call to your questions, I would like to highlight several virtual investor meetings and conferences in the </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coming weeks where I look forward to reengaging with many of you and meeting new investors. Caren and I look forward to participating in these events with you. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First up we will be conducting virtual investor meetings with BTIG next week on August 11, followed by the Virtual Canaccord Growth Conference on August 12. In the month of September, STAAR management is currently scheduled to participate in the Wells Fargo Healthcare, Morgan Stanley Healthcare, Sidoti &amp; Company virtual conferences and the William Blair West Coast Virtual Field Trip. This concludes our prepared remarks.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator, we are now ready to take questions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Questions and Answers</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:bold;"> [Operator Instructions] </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay our first question comes from the line of Chris Cooley</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you. Good afternoon, and I appreciate you taking the call and Patrick welcome to STAAR. It's good to work with you again.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley Analyst, Stephens, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I guess for my &#8211;sure. I guess for my two, I was hoping you can maybe just provide us a little bit more detail about what gives you confidence in the expected sequential essentially 20-plus percent step up in growth when we think about the third quarter versus the second quarter, so you can get to &#8211; I'm sorry, 20% increase in sales, you get close to that double-digit growth rate in particular with China in showing kind of a 24% growth I believe there in terms of units. When I look at the prepared remarks and you mentioned obviously much stronger as you came in, in July. But maybe just put some additional color around that and what gives you that confidence in the 3Q step up? And then I've got one follow up</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure. Thanks, Chris. The confidence in the sequential growth is really built on multiple markets that either did not suffer greatly under COVID in terms of shutdown and/or have recovered very effectively since I would say early to mid-June. So as we've been looking at our July results, we're very excited about what's going on in Japan, in China, in Korea, in most of Europe, a lot of the rest of Asia Pacific. There are continued challenges with Middle East and Latin America and we expect them of course to come into recovery mode sometime. But in the near term, we are feeling very good about the real resurgence in July and the peak season in China has on several days hit implantation records. So as a result of that, we feel that a sequential growth of 20% which would equal double-digit growth over prior year which was record breaking for the company is looking very good.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>Okay, thank you for that. And just for my follow-up, as you talked to a little bit about in your prepared remarks with EVO Viva now launching in Spain, Belgium and Germany first but obviously marketable to all the countries that accept the CE Mark. Could you maybe just talk directionally about the margin structure there as those lenses will be manufactured of course in Lake Forest and Nidau coming back up </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in early 2021 for the traditional EVO ICL. If I remember right that facility used to have higher margins in Monrovia. So, help us think about kind of the puts and takes there on the gross margin line as you ramp up for Viva and then get ready to start Nidau and of course Monrovia goes back to normal production levels. Thanks again.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sure Chris, thank you for calling in. With regard to our EVO Viva, initial production will be out of Monrovia. Our cost per units will blend well with our current EVO lenses. And so we would expect our gross margins to be in line. In terms of the rollout, the staggered rollout is designed to provide us the opportunity not only to very effectively work with our surgeon partners to create excellent experience for patients and to manage patients expectations expertly, but also at the same time to also put out a pricing strategy that we believe, with strong gross margins, will give us a very nice profitability profile even ahead of the opening of Lake Forest in 2021.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Chris Cooley, Analyst, Stephens, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator: Our next question comes from the line of Anthony Petrone from Jefferies. Anthony, you may begin. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oh, hi. I apologize for that. I was on mute. Thank you for taking my questions and good afternoon. Caren, maybe a question on the trends in China, you mentioned 20% share by the end of the year. Maybe just to level set where you ended the quarter in terms of share in that market and then maybe more specifically, where you're seeing gains on the patient, and is it still mostly high myopes or are you seeing a fair amount of share gains also from moderate myopes?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So we definitely are seeing share gains from moderate myopes. In order to get to 20%, you really have to be going down the diopter curve, because the percentage of very high myopes is about 10% of the total. And we're somewhere depending upon -we don't have a really good grasp of what the total refractive procedure market is in China right now only because of the fact that we know there was some reduction for several weeks. So we have a pretty good idea, but we know we're somewhere in the 18% range, so we know we can get to 20% by year end, in the trailing 12 months we're probably there. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right. And yeah, that's helpful. And then my follow-up would be and I'll get back in queue, is just as we look at the US progression you mentioned second half of 2021 potential launch, how do you see that roll out progressing within the first three years? Should we be thinking a similar ramp as China post AIER or a more moderate ramp just consider that it's a bit more fragmented? Thanks.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>Right. So you pointed out the difference in that &#8211;in the US market we have mostly smaller clinical practices or chains rather than the very large practices like AIER and hospitals like AIER both public and private in China. However, we've been doing a lot of work in these last several weeks. We actually implemented a program called refractive restart, which I'll report on next quarter as we finish this program over the next couple of months. This program in the United States offered to many surgeon practices who would become strategic partners or already were, the opportunity to benefit their patients with a lens that is </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sold to them at no cost. So that the surgeons could then provide their patients with an opportunity to get visual freedom at an important discount. So the surgeon was also able to improve their business results and we are up</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> w</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hen you add lenses we sold to lenses given away, we're up 65% through this promotion up till now. So we believe that this excellenc</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e, </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">especially when we add the feature of EVO without peripheral iridotomy required</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, w</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e believe that we will have a very quick ramp-up in the United States, maybe not at the extraordinary levels when you have such a big provider like AIER as a major initiator, then I believe that many of the key KOLs in the United States are going to aggressively promote and aggressively and happily implant these lenses in many more patients.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLCQ</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks again. I'll get back in queue.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thanks, Anthony.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Anthony Petrone, Analyst, Jefferies LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our next question comes from the line of Ryan Zimmerman.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you. Do you hear me okay?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.<font style="font-weight:normal;"><br />Yes. Hi, Ryan.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi. Thank you, Caren. Patrick, welcome. Couple questions for me, just to follow up on the China commentary, Caren, I'm just trying to reconcile some of the comments that I think in the early part of your script you called out that China was continuing to recover &#8211;its recovery and growth. But just based on the filings, I think it was down about 4% in terms of revenue for the quarter. So can you just help me understand kind of when that inflection occurred, late in the quarter it seems like? And then just backing into the&#8230; given the math, ASPs were down a little bit on the unit, and so I'm just curious if you could comment on the trends for ASP expectations over the balance of the rest of the year as you move into more moderate and low myopes that may compete with LASIK and then I have a follow-up. Thank you.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>Okay. So, we actually were up 6% in units in Q2 in China, but we definitely had way more lower diopters competing with laser vision correction procedures. We actually we had to make for the first time -1s for China. There's so much interest in getting rid of glasses and contact lenses. Literally the waiting rooms and the lines into the hospitals go outside and around the building, so there's tremendous interest. And in comparison though to last year, you may remember that we had another big spike in demand last year in China. And as a result, we did sell more inventory in Q2 to prepare for Q3. So even though China picked up very, very well in the back half of Q2, we still have a comparator to prior year, where Q2 was very large. And so as a result of that, the good news is this year in Q3 we hit a record in July in terms of the quarter. And what we see going forward is that we'll continue in through August. And so our confidence in China is strong. We do see mix being an important actual predictor of ASP, but we see ASP impact of less than </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4% for our entire product line, even though we're moving down quite aggressively the diopter curve to lower spherical price point</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. That's very helpful. And then I want to ask a question on the trial in the US, enrollment wrapping up by the end of September, six months or so to get everything together. Why &#8211;it seems like a very rapid turnaround with the agency and I guess what's your confidence there that you can hit that at the back end of 2021 in terms of getting that product not only approved but then as you said commercially available by the end of 2021? Thank you for taking the questions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You're welcome. So we really had exceptional meetings with the FDA when we got the IDE approved. We clearly understand what the primary endpoints are that we need to achieve. We are in a safety study, not an efficacy study and we need to meet the safety priority points we're certain. And if we do that, we believe that what is left for discussion, if we have a clean outcome, would be on a relative basis quick in terms of which would normally have if you were, for example, trying to bring a product into the US market, maybe you have 100 implants, you don't have an effectiveness record to speak of, and you have a lot that has to be proven. So, on a relative basis, one of the reasons, and we're grateful to the FDA that we have a shortened timeframe, is because you know immediately whether we're meeting these safety endpoints. So that gives us confidence with all the excellent discussion we've had that we should have a true standard meeting &#8211;100-day meeting and then hopefully really good follow-up and approval there</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Ryan Zimmerman, Analyst, BTIG LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. Thanks for taking the question. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you very much </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our next question comes from the line of Brian Weinstein.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLCQ</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, Caren. Hi, Patrick. Hi, Brian. This is Andrew on for Brian. Maybe if I could&#8230;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, Andrew.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">start asking a question on sort of the funnel their signing of new partners and how if at all these conversations may have been impacted by the current COVID environment. Have you seen any sort of acceleration of activity with those partnerships given your growing share here?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>What's really been heartening and I think a great testament to the partnerships is that we have not been asked to modify agreements. I mean, there had been a chain situation here and there where we've made adjustments along the way. But just about everything we're doing is on track, on schedule, renegotiations that are built on growth not built on lack thereof. And so, overall, the funnel of partnerships goes up as we build more and more new partners around the world. And really, from COVID-19, we have not seen renaissance to hedge or to be fearful about volume commitments. It's clear that based on the constant </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and open dialogue with our business partners, of course, the surgeons themselves that we would work with them effectively. And we have in certain markets, like I mentioned the US and in Spain, where we have a program for first</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">line workers in markets around the world, we also support in other ways. And so, those partnerships continue on with that kind of strong emphasis.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">That's great. Thanks for that color. And then, I guess, Patrick, maybe one for you recognizing that you're still pretty fresh in the chair. But I mean, obviously, Caren, Deborah and sort of the whole team there put together a really nice strategy over the last several years. But I guess maybe from your perspective, could you talk about some of the areas of investment that you might have identified early on in areas where you could really accelerate growth or press down more fully on that strategy?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yeah. So, I think it's probably a little early for me to put my neck out there too far at this point, but I would say that what's really exciting to me is the overall size of this market and our best-in-class product and procedure that I believe has a real good opportunity. So, I think anything that we can do to help commercialize this product as we move forward both with EVO Viva in Europe and then certainly with the clinical trial with EVO USA. I think those are kind of the areas that we would certainly focus on as a company which is very consistent to where the company has been talking about with you guys on Wall Street for some time, but I'm super excited to be here. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Andrew Brackmann, Analyst, William Blair &amp; Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. Thanks for taking the question.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our next question comes from the line of Bruce Jackson.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi. Good afternoon. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hi, Bruce.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Patrick F. Williams, Chief Financial Officer, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hello. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So, looking at the Viva rollout in Europe, so you spoke about focusing on patient satisfaction and having a controlled rollout. Maybe you can give us a little bit more perspective on how that might look in terms of the trajectory over the next couple of quarters and what are some of the things that you're doing specifically with the practices in terms of like training, patient selection, things like that. And at what point do you think you can throw the gates open to the entire market?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>So, at this point in time, we're finalizing all of the criteria, the marketing materials, the patient questionnaires both pre and post implantation. We are building on the success of the two clinical trials that we've had. The results of both of those trials will be published, we believe, in the next 30 days. And taking what we've learned then adding with the initial surgeons, their experience, we will build what we believe will be a very strong playbook for 45-year-old to 55-year-old patients seeking visual freedom with </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our EVO Viva lens by, I would say, the end of first quarter of 2021 so that we would most likely be opening this market completely by midyear next year. So that's our goal.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It&#8217;s </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">very prudent with this extraordinary lens to do this very effectively. No one can tell us better than the surgeons and the patients on a much bigger scale over the next several months how this lens best place the neural adaptation and the opportunities over time. So, we are very excited and we're very ready to go, but we're going to do this the right way and then open the doors.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. That's great. And then longer-term, could you potentially then get in a situation where you would add in, for example, direct consumer advertising on top of your standard marketing campaigns?</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We actually are doing direct-to-consumer advertising in many markets around the world. We're actually have been out so often because it's hard to do channel checks or get recognition of what we're really doing around the world. So, we are preparing a streaming video that we will be releasing in the coming months that will show everyone what we're doing in markets around the world with regard to consumer marketing. This is everything from some exciting testimonials, from celebrities in multiple markets to extraordinary campaigns on very large outdoor venues whether they'd transportation venues or sporting venues, et cetera. So, we're doing quite a lot of that right now, and we'll be expanding that over time. And I think, of course, when we bring EVO to the US, then you'll be able to see it front and center here in the United States. And frankly, we can't wait.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Bruce D. Jackson, Analyst, The Benchmark Co. LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Okay. That's great. Thank you for taking my questions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Bruce.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Our last question comes from the line of Cecilia Furlong. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Cecilia Furlong, Analyst, Canaccord Genuity LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hey. Thanks for taking our questions. Caren, I wanted to ask &#8211;just hear your perspective on your consumer outreach and marketing campaign in China just over the past few months, the impact that's been able to have just given COVID and being able to perhaps target patients more directly. But then also just as you're thinking about China through Q3 and Q4, but just the potential impact of COVID on your busy season and any kind of year-over-year changes either due to backlog of patients or different just situations for patients. I guess I'd just like your thoughts on that. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>Sure. So, in China, we're in this very enviable position that our strategic partnerships, the agreements that we signed, and the work that we're doing together with everything from small clinics to our very largest hospitals both public and private, and AIER as well, is in partnership. And so, as a result of that, that 100 million of participants in social consumer outreach in 100 cities, that is one of our partners doing extraordinary work because they have a very high desire to increase the number of refractive procedures with ICL, with EVO. That is mirrored in a number of facilities and a number of clinics. But what is really interesting is that the majority of what we're seeing is being done and produced by the doctors, the marketing departments themselves always in coordination, but they are doing more and more themselves. We have in our video library here at STAAR at over 100 videos of doctors who have done </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outreach about the enthusiasm of EVO. We have one very famous hospital, I don't want to embarrass, where all the doctors did a music video playing instruments and dancing to their enthusiasm about EVO to appeal to their patients. We also have our retail clinic partner who now has standing-room only in a very large Shanghai mall and in multiple other locations. And so, there's a lot of consumer outreach that social media, that's kiosk related, special event related, but we're talking about millions of touches each and every week. So, it's quite expansive.</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With regard to COVID-19 in China, what we are seeing right now is China is very well-controlled. If there are any outbreaks in certain areas, they are quickly got into, and there has been at this point in time since busy season began no disruption in our business. And the amount of interest, literally, waiting rooms full, lines outside the door, there's just a tremendous enthusiasm for getting visual freedom in light of a pandemic. There is no doubt that there is more interest as a result of the challenges of contact lenses and glasses with masks, et cetera. So, in China, we're seeing I think some very excellent numbers at the beginning of busy season.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Cecilia Furlong, Analyst, Canaccord Genuity LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. Thank you, Caren. And I guess [indiscernible] (41:26) if I could just ask in Europe following EDOF approval, could you just speak to the initial interest generated off of the approval and just as you look going forward the impact you think it can have on your broad business and the potential to really accelerate EVO adoption overall.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Well, yes, I think having a EVO family of lenses definitely gives our surgeons the opportunity to expand from our typical 21-year-old to 40-year-old setting all the way to 55-year-old to 60-year-old should they choose to. It also gives our surgeons the opportunity if someone would come in prior to EVO Viva and really want to get rid of their reading glasses they might have to give up their natural crystal and lens earlier than necessary through refractive lens exchange. So there's a lot of enthusiasm about not having to make that suggestion by our initial surgeons. So, we see an uptick in individuals regardless of age. We're really interested in having full visual freedom. And we also believe that in the early months, it's going to be more about the quality of the experience than the number of lenses that are placed. It's really being able to track multiple different types of situations with individual's needs and lifestyles and desires, and then being able to package all of that very easily for the surgeons. So, the way we market, let's say, in the second quarter of next year will probably be very similar, but it will be much more specific in terms of recommendation. So, I think, overall, you're going to see a lot more volume, a lot more specificity aimed at the patient with much more confidence about what that outcome would look like. But all in all, we see volume going up, and we also won't make a situation where our patients may end up having an EVO lens in one eye that would be their dominate eye for distance and potentially a myopia lens in the other eye for reading. So there's also that combo that could potentially also occur in certain patients. So, at the end of the day, I think overall, the EVO family lens has becoming much bigger part of the business model for the refractive surgery.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Cecilia Furlong, Analyst, Canaccord Genuity LLC</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Great. Thank you, Caren.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thank you, Cecilia. Appreciate your calling in. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operator: There are no more questions.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Caren L. Mason, President, Chief Executive Officer &amp; Director, STAAR Surgical Co.</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">Exhibit 99.1</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">So, thank you for your participation on our call today. We look forward to speaking with many of you in the days and weeks ahead. We appreciate your interest and investment in STAAR Surgical. Please take good care. All the best to all of you. Thank you.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Operator:<font style="font-weight:normal;"> Ladies and gentlemen, this concludes today's conference call. Thank you for participating and you may now disconnect.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>staa-20200805.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-08-05T00:08:46.3102076+00:00 -->
<!-- Version            : 5.0.1.476 -->
<!-- Package ID         : 50ea8424e897458085bf3ed531f5ee62 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:staa="http://www.staar.com/20200805" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.staar.com/20200805" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.staar.com/20200805/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20200805_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20200805_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>staa-20200805_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-08-05T00:08:46.3102076+00:00 -->
<!-- Version            : 5.0.1.476 -->
<!-- Package ID         : 50ea8424e897458085bf3ed531f5ee62 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>staa-20200805_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-08-05T00:08:46.3102076+00:00 -->
<!-- Version            : 5.0.1.476 -->
<!-- Package ID         : 50ea8424e897458085bf3ed531f5ee62 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.staar.com/20200805/role/TemplateLink" xlink:href="staa-20200805.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="staa-20200805.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>staa-8k_20200805_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20200805.xsd" xlink:type="simple"/>
    <context id="C_0000718937_20200805_20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000718937_20200805_20200805" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000718937_20200805_20200805" id="F_000004">0000718937</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000718937_20200805_20200805" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000718937_20200805_20200805" id="F_000002">2020-08-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000718937_20200805_20200805" id="F_000003">STAAR Surgical Co</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000718937_20200805_20200805" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000718937_20200805_20200805" id="F_000006">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000718937_20200805_20200805" id="F_000008">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000718937_20200805_20200805" id="F_000009">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000718937_20200805_20200805" id="F_000010">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000718937_20200805_20200805" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000718937_20200805_20200805" id="F_000012">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000718937_20200805_20200805" id="F_000013">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000718937_20200805_20200805" id="F_000014">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000718937_20200805_20200805" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000718937_20200805_20200805" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000718937_20200805_20200805" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000718937_20200805_20200805" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000718937_20200805_20200805" id="F_000019">Common</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000718937_20200805_20200805" id="F_000020">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000718937_20200805_20200805" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000718937_20200805_20200805" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140382868482936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  05,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR Surgical Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MI6J//X7W*+F?&^[_$L4/4$L#!!0    (  &L!E&7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @  :P&43JJHN=  0
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M?P%02P$"% ,4    "  !K 91!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (  &L!E'+VQQN[0   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   (  &L!E&97)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @  :P&47@9&KTX!   /A   !@
M         ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   (  &L!E&#J:4#U $  #(&   -              "  7H,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @  :P&49>*NQS     $P(   L
M ( !>0X  %]R96QS+RYR96QS4$L! A0#%     @  :P&43JJHN=  0  / (
M  \              ( !8@\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M  &L!E$D'INBK0   /@!   :              "  <\0  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  &L!E%ED'F2&0$  ,\#   3
M              "  ;01  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  /X2      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="staa-8k_20200805.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="staa-8k_20200805.htm">staa-8k_20200805.htm</File>
    <File>staa-20200805.xsd</File>
    <File>staa-20200805_lab.xml</File>
    <File>staa-20200805_pre.xml</File>
    <File>staa-ex991_25.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "staa-8k_20200805.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "staa-8k_20200805.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20200805_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20200805_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20200805.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20200805",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20200805.htm",
      "contextRef": "C_0000718937_20200805_20200805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-8k_20200805.htm",
      "contextRef": "C_0000718937_20200805_20200805",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.staar.com/20200805/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001564590-20-038023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-038023-xbrl.zip
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M,>(9EH67U9[^<\]J1\/A,+#2@E FA&XNAQAMI/5G>R EG*0&!"OR6._)2+8
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M9+GA5EZIK_Q)FG#\-3@7_P-02P,$%     @  :P&4<BP'DST!   TRL  !4
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MM(X$4RCO>87J.?T__6LJU)TU+D,'C]R.12>+R*<))"/LE@=>$'B3CCX-Q)/
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MC(8T=*-A'$_[/PR'V$+D Z?$COF(W1S:.:\,/'O&)6<<3!SZQ_\#4$L#!!0
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MY#W.VT?9T]>^OX</LI^\;VR>_<,5-GO6V-9A1'O'I*[:SC=Y]I,MG<E>V,I
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M$N>".5)D00(-O>0E_"*8MQ#+ B EQ+?HZ" ETTH4DC,<["KD6ES95ZR!2$]
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M+"YR&Z+;(EH*:)ADQVQ++]5FA[$*BQT'?WL:D3\<S<:!&W3TN<+12?CM7Z]
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MPVHDSB%$((Y1L%QDF$G8)J3:&'B5AV<6'N5_%]F)XWO3V, 8+G$2,#$$ZC'
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M?S_\;E^>,OP84W"@A+9@3$GXF3#@F^/8$&[Q37+UZ!V>@M [LAE-3>L A[^
M^.F<!7DP#GR][84NNA\&>G!^H+>V!SI6LK='OY_L'YS[?8QX[33.1TX]W);4
MPX>DTDHS^$JG%="]"@" 3IG280;8;+NPMA,T5&%:=5KQ![@8STA9L67"/E1*
M$BW1 ,MFYU>#69!#:WUQ.Y'Z+?-U/Y'F<6AN4*R_)O3\HMV2.&0T$]X>.F-
MDRW;P4ZSKX%3%$Q,V_GB5'&]9"P.3,.13TRYKP5CF%!>!;J12!Y/(L0N!(V1
MG:-8-NR4)9T+*)D 3JOSE8:S#:?)54CHWMHE<Z]4,O=3J-!/G.]02B3D&%J%
MEAZ?*QQ!"=N<<<9C=Q%8&@'\BEN' H*@ $C!#(B:\[>,[4/4'U2V1V6HY:?0
MW?]'D*%]W 5_Q(<-G5>)QP[3%&%V^&UOU..\)MSAJZ:G2:4^BOJE<>;!0:X6
MO,#=H>+_H?=*6BI)B#AI-9/<X9"9*#@/Y6LIG(DE  &41JL3.#"0H8W8T+98
MV+*O[)9LQ:JV5[:JVNP1+8;/?F .FL*@Q\=/O@&AS4EGZLIN1E^=N-)W+C;\
MDN!ZF)[T0 NIJ7&CL%<(M-SW@*"&>7CD+)VA+QNW4K+[D*X+R8XQW^?.4'U_
M. SM[1-+NV 22E5$X$V+ULZ5GO:/B3I]'DEIL4..N)%3>Y4G]]/(]-WS)D2Z
MRM>^?V//K*N$@GMZ:C:*Y!9G2F0O8WK[P1UBF"P=+&G/T:LLDA^5:/5=^KA>
M"6&+2/)MKM)<K=W(KFFE;XXD;*.'G3:(2EKWL8F#"H;KK6#00W54,(>EQ&IW
M0'VXLHAW;DU]]:HB=F+U ?3@E5:#Q]F\MYKC6&ZR__C+-X<'!]\"702"XM%W
MW=IS%!'%8)ZSPU!G!;E>2[,A#Y0;V87.#GW+G42[#D@OUTEM:VD[ UY9;@?&
M>=ZY0[L O@]Y8V#T+J*_)[DHX+^&&&J$.'&J:V]5"=T.IZA:6ATXQ0+S9'K7
MR$GB:'\,7<C&$(DS,FG[]H(,3XZ2U_".S#[@PP1EQ]>7]&W3;').N:4I8,W9
MX<*YUN9H5U<@/"^@.&S4R1TJAM/22]QQ(97SITX"SH;):?7JXX3]4-!X S:?
MJ6V5F^5XA#':=E2'7J 1E^FG9Z@XJI2))%+-&ETPL :#ZT Y:B?9O;X;B0+]
M4P G92P!+'P%.NK&][5V=N7TXU@4M/W7MCS<?!Z6^*^<%F/@RO%U>O&Y[[BD
M-:8?=VKP0_#NYY\#[?Y'TILGK"'YX&VU@:HD?,[+;:*^ J<ID)N*YG$5%[ N
M@8\#W4J [@@%IN.J#T!AT-.K[;GIW1S\+@"7,FN!H'C271_9Q&EOW?"-U/TK
MVS;M:\;>6+J38FB$3S[FAUIRPH0V!6 S5^Z!9WN2G7A)_6._,00A="M3_E!.
ML46H./VNT:)B^[K@ROM!Z[-IS#09=<*W':J'\TB/G:?$YY%#FQX<F=";A)P[
M4W)N7H9FQ(()A,W" ,,Z#US,"2DYJZ 1@WG 1 1(T\(RGZ_VYF1JGZ6BLR*)
M.3IEL[H#AY7H0EU_\/_PXL3(U<Q:SIORA5*I&L\F" ;/8S,/0L13&R*4*9-W
M++@&+H3^'1)YH%G(%BZRLDC253C0V["4*=Y-VK&L962JER^06T8\?#DJNZ??
MX($7G&K<NB7%YLE5)I"Q9YSP4G;4$?J9MD<0KCA#.\MVY^%_*&3#5X)L0/@I
MWVI.@JT@(!PV:=02CJ1U>3"&.E.=!EQ28O7*MG:U).//V5QC;B/N@F3Z6BBX
MW\HEI1$R\"PD5AJ?' %&("VW;<+4(=NZX):5";$5ZGZPD[41?+#>\$9T\"C-
M"A]6@Y+26A )1/9-,#VYBL$SRI-!C"$W-53XV#)1I'2'A(68WX]ICC--:(8*
MD:L ,[B]@QGL8 :?-\Q .H:PXWUX$ _ME.!%^PU,LN,9F9.H\6/J-]ZEHGXB
MNWC?CCHTS97_A::8T44_^1J!! -C)>?6CT)E-?CQP1=FFZ@/-26D3EI51EZL
MKU'Q&J<.5&4#XLYP>-^(_HW%$$QF&!*+PLDN>LG4J?H*8R3[!%A;(YPT,EUI
MU9M WH.S$.._5QX3L7-4+\/! T=5_--MVP9I#+$T$#MGLNVY(GM2IO\\]L],
M9#J<[-B)M".&[0KV+ZY7!&Y7.BO);RO+/A7]&>L9 DWQT&5!3"T0S6T!TIGM
M-MG)@>Q-][2@3H+_RVZ4D'-*T3+MX?F<?=_ V;E%U9I$+3N&I \LHC7'EL0;
M/N<Y#YF="WO%P%.$KVYC#64WM&\20'.@Y!7MXQ4<,WP\ZGO!UW:@ (3EQVQ_
M&LYKN867LB?S%XB^X4W1J<&%7E$TE/DF,CYKW#"7-Q@Z8PVSG,OB(30G$5V>
M@9KVCR+H0[,S_E<EV"^E5]2% "Z5??W9R-C3GA4[MV[GUNV279]\3B,.A?4W
M8P-_"WUQ5).K1Y[H,PN]H<69/T(YPMF<A._SX%=*+>+D+<[<Y[]H'W/#;\U_
MLN?C(F1/GMR_&N*Y(!_ 31B4X2L_IP<ET1E)27(,O0LQ^2& (R'&Y2;IKWZ>
M'U!QSKD&0,P@_3XT/R#SI4UBU.-4V=!@;-P?(91TPRX=(BM>VU"AWE+@VKB;
M\,V/^&A&,7VM#./#6T(]@\<BP^8<*VICF4:;J8+C[1&.;ZUE2G8#^TE?3 T-
M ;V@+ <>)LY\Q-TKJ<'G=BK"X6YTL'HKM(MR].F2*TWC,.4);(:P6D!LG).<
M<J/?3<>YTP$[K^=W>CWL0I1V!M^%V_<.\I_*Z$7BR<X$NL4VH;,!_8=VN&QZ
M3=QQW$)\$,EE1?J9TOD5=B]Y-["MI[90?B<;D HP\&FOL"V=[B\T<.#8QH$4
M\;+B0;&:N$624T.*279U:5?:+[9?H2DZ7MC7USMEC \C94TW;TR[PCW7R@:N
MG#AO;80XZ#L-X2!"S;Y0>*E0_&:*+GH5IURJQR.$7F8$0&.#XPB='-)47+#"
MZ:BU#8->-;;K=- DRB8/9,)\V^TIT S;P3?*.92K[Z@_3H$;4-':T1&J-A_:
MVA@I8CPXU.Z2^A2:CZF95AMYEYWALC-<?O^[OL"=9/>2X"TX H/T-P*:LU[W
MM9S@259)0Q\P1(!$O0X/'-0,B#!R^UG;T[31]F1S0@KR4VS/WT^$X<E*PZ2Q
MJ7)!(Z.D-XSDG\C:HOU3^G#4R][F*G^HIWASK24;<0MTB\:*T=/^-3M9\)MP
MK$&BMV(U!'8!CL'2"VCS7L2-CHX?OF!+0\R9J)OYI_S"27,I--W!?)H!8T;Z
M;+YD)LB_:L3U2ON).W/C,NSS=TXU?RVI9M4+)[+#F*N?^]QV:D',0FE=,/@5
M=CC0O>@9'0Y.M=;;)5 N2<.7H0,Y KX+MGEH.RU"QWAF%H<=PEW+DI]SE3CO
M1>B@A6]7:&^=?LYM<[4EO-(PG2F0D;?S)/O!KW'2YREJJ/2B 13$PP'46#E:
M 8VS91V\8L*JGDT9P%FL;&XV%9C%CN/8XS;PVDDW5\P):]"A5X"&-U)^+)B)
M[4([)^AM&;\B^)W74#H]T%EH.^6E!?7+],=A86J&.IUTW.#"\S*&L.XFZ;L3
MV\*CA98J>R4MY!@M36D,(D,7:O<?4!3FYR+4;(76%GPFXS9O$M?=ZE!V%9+I
M7^V2Z;MD^N>=3&]]%0@9E[#;:L]I,SX30L>FH85C,;2X":FJ"[=ZO:T88#>.
M&Y\Q950-54J_0_>^TK6,$=)'QZ=*)PK.,2FDB*YI_%EX-(CH0#D:N_$DW<>!
MP!;A^,33G*TOR4"P=%S]5981'05/5J1 /T&>K<[,&C@T<4+)&?CJ]I?9T%I+
MSAPA%63V7,3JR-L-;O10"V"T$U"D;[TD,T$GV&49"<=*I;>E5HI@>=B7L89Q
M;=H2$+N+/1]R3U<+-D]< VX!OP3H^=>>#-SRDKQ5?FED?DL: UF%1GK8[*29
M(Z<VT)->9$6%F#SR\(%VZ34]WS<E&9FP7(51<AUV&-^^1<4*O,)Y4)A-:M+"
M8UR:7WRCV ;V3:2>9#SFP)*"QY[:3?:WIT_:BXT]CBEZI=HT<W&0&20@^U6<
M^=$7;%F;U<JI:<N]5,40%GT ^#L&P([MGVW>N_-J_U0\ZOF5<%1'&+0WA)8F
MLK0?([W]/T?*=K&3MXMD'@ #NVC=+L[^QS%!.^%Y/\+SV\0T@XOUSI"A%QMR
M//_3H1LPS=[.CGF_2S:>W62[,]_;E=OID^R!1,\7R.B"<?C4;"XELN322\Z'
ML4U^4W%\-VVR&]__$X"+'US.VF&G$W8ZX?>_Y0\N0?WE N6+O9_SP,[$=8[(
MX0Q 0"[G),LHP/)&]/5<(LEY:;H:22<#L@_%"8+^0ZYJ-NKS!T)LP:>$H(%>
MJ_F78RUA"@PG7$Z%3(\RL3996S1NU2G!!N>U)"M(%\M@UMQOD,O:DP<C5Q5R
MA%T[5*4SU)'KL:4DG<<\Y181/F3M@7YA?F@=6R<]*IA @.%(M[X<01%#Z_#M
M_NF(0 )P@['S<[ALBZ:">0K:#F,)55L<K9&45#VKI,8T\P57A)1Y5B6TGQ$-
MB=2@74H*,F$ T5<J3M,N.)B+F_O?:D152E:[!6V DV>M=/J2]TN+=75"$#L7
M.&3KAW6FD7'[93=3MAH$Y'5QMT"BF!=ZSKAT(V83 WOY%H-!0(J&ZK2A_\L8
M!H%Q0485,J9!JHVTZ.BLY &>')T<_VU AQZ'D%M$F"3[9>=O7>I3]"KHYW=&
M1WPS%.)+X><Z2?[SKD4^A+61E)9)LY !E:U8P03WN3 EJ3,-H4I;)P5HMKIG
M(B-V9="([<RUXL(T6OH^ ".WT B,O=#L_NF@#A4&A5JLO0/1!HJ'8%Z2ZX!$
M"J,24!^A&&IN.QY)XU@_SFDPH5<5=_XKNE@B]X3>K.$1X'%KX^1"[Y<#CS%<
MKG;H"3;@-^8H[NL@F!*/#DQ,EJEH@"9E#&6G0^VX46?)FD]'*Z U%_HCN):U
MGZ2GO$ XI(M9*/R(=< A"X!9,[5G% HB]#2V4U;WI5VR?@OW2+ D>&9"6I*'
M#E&M9:PZ8T'!.^[IT!.IX+(^)ER0SB$W^8"R<A[P<!5U1D8"'8<D63@Q<\E+
M<*&B'D <' UXN>>'_&C!R*M:E8E@<M91Y]0 OZ?!X$0=<#:QS/%"&A:N6@;^
MM;9K!@5S&B_,Q_.;/(4@EPA$*H$BQFW50,:#^2AP;*VM-/3T2KO"3.ZN#2N#
M<'#L[,-O+VE'8?>.H^;:S1'-D3*5M5I$R/NDE$9@:/PZE6*!-.LLNP@K5#HH
M/RXI.GD6MS NQ2%*5T#VT9,-N68&+5T%",O7.PC+#L+R)X_53YS>);< BA7:
M .AA@<P#Y\^G3SY2M8)F2#OU_MH[F+-I/O1<]<30Q[%%UET1C5Q]#,CD)4ES
MMY=D'+O@R2YX\@<B_6QLOY2Z!"E).E><@ K+FB,DICV]L#IRU(LRUY: [!NO
M&R <I)7HN#@R:0S2DI&@Q3>H#_(!N@8H\*9;2*"#/EC FGFUV RQCB0F$# E
M]$ R#+N^J=6Z9>L>#S:@U-LHO[=PVRH?X6;+II'Z)3:+ @'LPFD<1E$H;!;J
MJW 516I^!7.>+PAJ,5))<,O&,S19$<1W';S^UCB-*C0*3#)GQE4,P!M/'I[X
MUXMK7<7TVW7"V+GW'T>#_%.JBV.858"(L4ZR9 3B2BFBQJV((*J/'AQ%^!V(
M?/'9\8.'<9.P,U%4$BM-0HFQDE%:Z6VP,]@L$"Q6<#9KJ[Q\Q0*P+G'AI730
MT'Z;V6Y#T]^7Y/DQQ*P&P0NM3Z$?!UAKN ]>0"E7^%IV]Y@"19XME@XM?\<0
M&_:59^RM^BS2;(YQ<8K,AY'*^QB(W)YKMW*]-CB:- OHJ]IAHO.A3 P=":6Y
M+\2/NWPJLB[522EMIRQ>J&/5H*:4%V $]K5!J46>A+>GC11N!&468PNQ&"4@
M]2((CSR(@&M3/NRT/K4>F'041LS.+"BWF./4S_)(2JWO7WE5P> [E>);EI%:
MHD473$/.O- QUHJMV^:ZI%BG.8*J=-B%;I40QB%,P0]M%^2R6B8*(F4W:\Q2
MBN]"#2S&Q_6FL!1*)VUX2: YO*%VK_96$W"?"DX4UP'S+138?9N>1 +L5C+'
M@49HD!&MKN%05/#QI>Q.7Z!K>J9 JDMX^V$L>H+2&NV5B(_IQS%HO/ K3 R3
M^@YUQ$.-(D>/>(N:2H[+W4FSLSO_@-T)/.(;K)==T?7.>OEH@!)Q'C@POY.Z
M2XPBNX>GD!7GZK:S.R;-]P\;+1MZS7L-N;?TINGY,VZ.&9IJ3JX..AXP)$6/
MX$]%D,@_6.RTZI?^3Z=)&4WT2R%Y<B"_98" HA!VHKD[Q#Z\X(I$[N(]GU0/
M7@EI$LIKTRI92QKM;7T3X4JSOJZY6PBJ@<&EJS2OZ" >V0N$/6(-I8C0J?BQ
M+7=F0=\M14<!)L#>*G-$2,YWZ$$=>(*ETXVMSUSC:P2723/C(F6I0;^;31PA
M&AU4,#]XY/@W*0;$:33PA#8%890+MPK%MQME&EX/3&'P;2\EL/ASW%8['?[&
M=.Z[HJ3N"$KJE60N0B,IR#^@\)W0+4N.0PGSI6-4UH$6A9,R&NT:R?\  Y&M
MB&@HWY44@88^?4ESF1FZ&[.P@"DO6UK$*"1?@AB47")<,Z05NEYVH/0'D> 2
M@L7ROQRY6AJ D4HLE4!E3>4U$+ VFP2W*FC4)"<DT36AE'%":0EUS9' T$T^
MIQFJ[=RCRI=UC>1P&COTWM*&1?S"X;.*Z?PQ2C\+P)><49PTW7FJ_TBWC/4(
MN@'T*V668525 )3P]OS'6$$."*RU;ZI2'B:KFHOWPWIO[^!./EH;UGCT;L:U
M+2-*T4W!EN 6;#0X.B-Y0'!3)N[,5_U2$,FN"^L'$>+@NLS+"!H,HBT&ZUP%
MP,TW.\#-#G#S)S7TN2C&QWT^MQ]9@43+D8J<]W9H/1#)6()>R8=&)?F82P:,
M,ZVMSNR@[R4G-#0S8%*:I,]!X!_5;%$=TENA66$N^??CA&90,T-&H*+:R2IH
M_8'L4]BSX$(S;/:2(&DN"T$)A[RP+#@HAND^=V8(4!I4/6W/_#_XL>!KH5^&
M\^L"LS?B/;FK!R^^&;KK:%,(NUPMD$[;!=MV3N;[B[MS(U!8IN,\D'3_K7PS
M()#R@-?)A[(N239+V]]&J9D+3U[HOR+P)O">,UA;F85GY' L E8)5FHC%F:P
M9&,_O5CK]<!.?6,66A(T^+_KA0<OEC5+-6K1<B7 E ;^9>Z6$GNOQ#J@$=<A
MTZ6&<0@P25Z/[3]I'D@;=B4*.=?RH]!X4.V[M.S,(->-?P 5+W;U@&9:,IFS
MZ')(@)LYTM@"L)"NHG+YP$TOS],7BIZUC:T^N;=AJT5C0L/*J6.O15[A]7=N
M]'M2'+H+LD>3H"C:X$ _<C6Y P#DJ0-]93WF?UJS$.3'4+MXO1V(NV-UGXBV
M5'MRB08:E=/.M#2#2KH*Q)#WV0P5>$J<QN@,*4A(>R-'S,[@?'.+8\7)H#&P
M=I$29S'#!,B^=&W:N8'M-MJ<-(E[!>I](K9&Z%0#';M6C@;,T$*+1M"6%Y",
MA/%O/!FF#M!)-?. 8BR]^(G5*L$98H"!6DX&P+XKUR"&*A&F>QTW+"5%(5V9
M!]2(&H;59L!W12Y:08G&6_S]Y&@2QRJ&";SRM*^?J*&QE3H\8>:+GIU^GI#0
M/%A03DZQK,P5W78:\U@KJG-H-8S)Y(@%]"C'3:1+-08)Q3?O-_R(5UC(DZX!
M^(LI[+WVVU+YN+Z$Z66;V.U:'/ =<_S.6GHOJN[Q>3/I KC,3M N-6ZA)T/P
M1Y+=UN]0"^]YQ61R'TS"_":JX26MP3U;%PL<O5=**8#WXO%6'ZN=0.WR5!]:
MZG+19;OC9N?,O4>QLE7E=_IK=R#^B9>&]XM&2.S(294..ZJQZW-P6)GC@F$C
M*X_"07;ZV)]D#$L=R)8S %1:M#>#82=\S6>"BD'<'/<=FDH'_%\H&!RZ)B<D
M0T+E/,3R\+ %-TP#D0\'YKB5TS:7 TW +WRN;-[8F$3I'I2(/V2YTZ@@AP/:
M46Q4DN=IT\C!<Q_ZE*2CX50/NJ;53!829\HJC5,>'B,_Y!:=S-ZAE4X<5@G-
MI<3[#S,&OHFU\%]( Q4DNQ2KH"7F$C_9Q1%W9LZ'3O:^*QSG8%_P.% ^H] A
M[QH.$0E.949G>279"423 D%< SH?9R1+*^+-'6L-?URUN4)U9)L%+[,VM "M
M-F%2< GW3].".R/U,UKL&+A] K*C[8L"\?J@%]9^*TPW4,)(:1F3%\5.'W09
M/Y@O1^!.KV%Z?Q3EH2M4N[!E6NP8.RZRVKJYGY4Q-:FQC/7P2"!2-(U<HRE#
M)&G"#82SOXHI[5PQB"!<:QRJYO+8;$#P-X'\)L10PT"U8ERSG#1QFRF4+^(K
MMV[O(2NSIQTZ;B?_C$U76FMYX%L=5GB@5P$S<V>'F=EA9OZD&CT70?NXST>2
M)28LN!':=).G^9P\9540[K; .!F('5J_E8- MSTV;QAXR6:*Q&*'! \2#)7E
M6N#IA@R[DOF[6/5)0W"M^;W><AYH[DTUN22HD\N"?CGNN$;YZV_;RS(B/BQ6
M35\RL8D<1]QA:=R/IN;B=*[W#WFH$9CJ9\^P!;9XP3/7(P?5=6E/QHC6"H1^
M\<SA(G>N4IRZ^1S42'1HVRVG(. *E%-%' RF&, & .4@G75"<T(7]/BI*<U*
MK(;XS"&SB%X!\@0G# ]YZ/0E;Z=)KZ&N7HA8N&DAJ%Q\X'6[GG;)"3/$M?GL
M^H"I,>82Q?H')Y3WS0YZM L0O&>R(X4>198CH,YMLP='-T78Q.;(PE F#<6%
M/22BVP>DC!P0:",&P..(2Z-DEXE3TOT2"*&2=DGG0LB!9FE@@8YL#=$?*.@N
MAJ:[W?F^.]_W V^3E.76Q""1R"\-<^]"$8[-RMX 4H4S"O4?[SP4? EZC:2?
M=EKD56$LS\(()0P=%06=C:BW*!:6%!8P9]B(BOD+55[!A6PB 9$V'#XWF.0,
M$YI8[4S>T75+<>I*FQA^ZC$VEES3\+Z*)&%W74Y:^3E^V^+0Y5H5G/7)N+1<
MY<UH7K$L&CO7=X^S'97!4(:<%,-PPIFC?0,<";$"&IF$$?@'@.Z1!/&)CC&0
M/^\0/PR#H>>-S9FH=Z"CDE;1M&8XES/F@F\CX0W]S^9ZF;&<,=<KKXS^", 9
M?,C3RQ_E&6QE"T+CL"3#'"E%9.@5+4WHV4ZH_3JR^,BZD.]/_XYHI\18.1HJ
MH4:@^, Y)<1&\!$BH9'V D2(5.,$V@$5K+3DE=%,UH+2*BQ8D:6ZZ:*V@/+X
M&<W&:<5-/6'U7>^8M7F7/]N9,N_7E+F0#G"YV;$![FR'C\^GLT,)?%I0&A<8
M_!8H[;XM7.5,]JAO*B9NWWG9[U=/C.<W.9GNF]H4S'CXF"PA$!-<E9/I!WLA
ML1O\VN$@BHV4F%I8*3K;TT!+J/V#3'.N^ 5F:&#K%;.8+%$Z_@HIT#GO, _]
M"?BF,5"VPOZ8D0R*Z2YQ8&TWH)%9J657VX_=%;Z%,$4(&P6>J>T-]'<TUH59
MD24-,[D; G><^1<?JM*J=LENH6Y/ZMO;D)5G:W6 H\OP0S>&YS?YJ<]O25!-
MVE#AA4*@(FF:((,,4S;MVPW9L#BRA+^1W+6 MY?L%DT.Y[G8VYK3)K6.S?JR
MYW<#YW'EYU+S'@*2("Q%0U$$17DP,2XBZQ\;5\?:IF/R$/B7#!'@H0E/O,0W
M!3.P4T$[4^4#YZ;>.<5_H"G^OM'H]]!R2!Q6]OUBL+\^<ZP-5KZ5R(3XI!S8
MXT(X5XR*<$7W#+P:,>H 5AUDT<T0'SB-F?GH)\>:0PX<G L)+($VD/0^^_<8
MQ^#(0\_&[D ")T#VOM B)'=&XY4!'!T_?"&506# <!P_2-YBJ#)^0U<;&C48
M@9> .$JT!E>[PJU $(R[M9ZACN<U.WV'2PN.6^B]F/"#C1@^(0*?ADS).(;!
MTQ;B2HA0A )TX;LG@<I*VA1< T;/*E!VI,F1GCL7<=>[&<.ASFS2$$IF_/C^
MDSS6-8E/AM$M7=.0SB\E6#S<:69@$W $AI5P\I6NDIP.@1=: UFA_Y*2G72!
M_GII?A$"ZG'XJ[56?RG'4XG)TL*RDNSRR*Y4>FSR=AM_4B(FU@5QC)0!DGV7
M]D\ROX+Y4B;[-%XX)CT9[L&HE, DP,+(D39L></M!W!9ITHGQ'*P_/P[1I_H
MF%&"*W?BM[L*D(N#_1WF8H>Y^-PQ%\$@GVIU+=";B[YUIEUB^[*:#$H .Y?U
M, T2?>;":03?0/CB0_,1NYR:IC%@ 9"$6Z!%#^H #>&0'&_I^!*E DB7A-OI
MY.V57HI44@E4O62A%3LV#%!&K0%ALUJATC;^;C!F7RGEAKP$J;'&=L:%DS8<
M2*RBP Z/2E-.Z]%C]]"L3UJ!\-F0A-5/8'<OC,OXU%;ZE!BE%TZ/RA=&O:B!
MV$/Z]<5@^?DS5 KQY81EHOH\N#FGSI/GQ<3Y,#88#$P_0O^F;OAX2."/:V7U
M/!<PH>^+!;R&X(Y9[:9G3]5NPO,DKL\1>W1^VN%>MK)OX_1/8/]*;4XU#\UP
MSL>\"$[\V(XO]C+<&^#JY(;-M.+=\ &]@8RPMF]3;A\NOLZ'0YT;2G ? &G^
MD"=T;K&,^D( +)FQX"=+O<\IO5Y-PT4?@Z;GYB#!&@A41C$SGT$OU)VP68@-
M!,(A;8*9;W7 !/%$KOTO0Z?+ "(9]HGXVVE[RT0!S"2WV%T [:0Q5CS38)3,
MD'*R2U=H:T_,.%[)]],NVF?RL7:HU'Z?YPQD9B)!8P>XW+)[DY:?TL59.X*R
MG;DT[>GYW-FV4Z*B$6KL.3<8\#K:1D),SS;V-"+7I X\GLEZ[< WN[#@^RQA
M'S5J/TK:<?T7#=&UI()J1P[T?V?_^];!W<.O_D_"J1U"9:<)_81T)>$T[H.G
MCV);DA3%(X$I;BRC:=Z (H^[<FYK9K5!.&P6*2A"BQ/LP21*)U4ZXT:J20!Q
MJ&TA@Y*[AYDD=#EM/)@R V=;Q/C% !YW==\FVX%%8DHORE+)17;9E5V4[(.#
M@7"@;A!W"2=)+(*#2,IHI$,OGU9)]VUI:,2!KX1^,*6L$< )#E*)5G$L>+/B
M&3P\&)5@W-H?_MGJ\1P\  !'MZHTZ)]?I5=(3R0V9XJ%YZH5#P)4L>+?8:2D
M@W"$,IQ'J&APH"((QAV?Z7D1:&XBA6MT7ABLY *UC6L8'8M7" <[CRRAYNJ\
M5A"N](+:=(S4+1HZ*50C,: 7]$8NH(=KB\H>!%)"OB")7,G/7TMP7S'H6X[#
M.4<(7+.ZX*'5N;@2_7RNR<7IAF=NNRXG@JP FZ&AP<Z3GF30\N2@]8@YBJ5;
M:3F2F=L %-N*>TD@34<"*V_+-HLDE;R>HPYKBLP1&JB0[F%7)&*1IU;C5=%E
M_97NK6$U:;T5BHL&E/80N%/1C]S"#*\NE5\W4C2G:2)F*AX\NR&%0M(O1F"2
M1F&C;Y@TNB?:T<G)4;F9Y;VMGBT',MM\P%%OI:?HL33)0PD:C5B,0M,Z9<E*
M$>BRB&&/K6UL]E99O!M74.C\MI;LUC(MGXCU#H*)B\Q<4S5$6T>Z XW2X5RZ
M+J+L&-_.ZQ$J4T<EJ #]+6&X:Y5;PGJ5<#1K+BTN,4LABSG?6>B0\_2C\# L
MNZ&CKPQV<:B^$^,[#BYITZ:\46+T<["?F_2IIF!C <DNB>P::2[/H]3MH>3,
M,MA^%=!M(LQK#H/PUCN/.I;H=T@R&FXL!Z41E'3-:HEW/CPLTEYV$SH/A@:"
MHF!*0!EA:> 'VHBP8VIIJ2X<<- F6V[\RIEX6]:5')P(UZIZ&RN9*I32T-Q,
MXY\8Q.CN^)DO"E8IT1\=(B^QTC+6[;"#9S;#"34BZDY.*1ZO>*L!N)F44B!F
M$VX7K;.E+VT5MT6B3'F'-)N=";9SBMZ[4[23J9U9_]%P>KKQR( B9Q>QWTY!
M&>"#D.CYU89C?&3D;@#R:=00]F+MQ:+8(74_<PWP&66:#P!IV66;KU2V^=.+
MU;N#J@X%5/6ITVWBWJ:%$YL *&)L4FA]%@Y$<B5+E%Z\LN+6Q>BO-BZ/5"5<
M#2<5G<%% N6)>G;VE/Y:6"/][<W6R3NDBC@#'#G<T4MCI(TFV;-*T$KP#ID0
MNC! J1UI9(RKO9'(%G^?[IZ8F[N\SJ?#Z#\A_SCD]FB\%3*1N61/"U\755\B
MH 19NRX-X1$>*BS+X':I3R*LVON+>?[-AC/"R*CXNJ;3;+?>[W>]__*7OUSR
MJ?R,[)'#3V>/?'=CZLL-S)(;BVY9T1__'U!+ 0(4 Q0    (  &L!E%9/Q;U
MK00  +$6   1              "  0    !S=&%A+3(P,C P.# U+GAS9%!+
M 0(4 Q0    (  &L!E%FK/DI(P<  )I)   5              "  =P$  !S
M=&%A+3(P,C P.# U7VQA8BYX;6Q02P$"% ,4    "  !K 91R+ >3/0$  #3
M*P  %0              @ $R#   <W1A82TR,#(P,#@P-5]P<F4N>&UL4$L!
M A0#%     @  :P&41P>OK=6%@  BL\  !0              ( !61$  '-T
M86$M.&M?,C R,# X,#4N:'1M4$L! A0#%     @  :P&43AW*P$</0  EV,!
M !$              ( !X2<  '-T86$M97@Y.3%?,C4N:'1M4$L%!@     %
-  4 1@$  "QE      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
